2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Apoptosis, Pathogenesis, Genomics, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

4982 Targeting G9a elicits ATF3‑mediated oxidative stress and cell death in peripheral T‑cell lymphoma

Zijuan Wu, Boya Wang2, Yongle Li3, Lingyu Zhuang4, Zihan Liang5, Ruize Chen6, Yi Xia, MD, PhD7, Yan Wang8, Ninghan Zhang9, Meifeng Gu10, Haochen Tian11, Lei Fan, MD12, Wenyu Shi13, Handong Sun14, Jianyong Li, MD15, Hui Jin16
1 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
2 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
3 the First Medical Center, Chinese PLA General Hospital,, Beijing, China
4 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
5 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
6 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
7 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
8 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
9 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
10 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
11 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
12 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
13 Affiliated Hospital of Nantong University, Nantong, China
14 Women's Hospital of Nanjing Medical University, Nanjing, China
15 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
16 the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

Peripheral T-cell lymphoma (PTCL) represents an aggressive heterogeneous hematologic malignancy with limited effective therapeutic regimens and poor long-term prognosis; standard CHOP-based chemotherapy yields high relapse rates, and the clinical efficacy of approved histone deacetylase inhibitor (HDACi) chidamide is severely restricted by frequent acquired drug resistance, creating an urgent unmet clinical demand for novel epigenetic therapeutic targets and rational combinatorial treatment strategies.

We conducted high-throughput screening of a histone modification compound library across multiple PTCL cell lines and identified the histone methyltransferase G9a inhibitor CM272 as a potent anti-tumor candidate with nanomolar half-maximal inhibitory concentration activity against PTCL proliferation, and verified consistent growth-suppressive effects of multiple independent G9a inhibitors including BIX-01294, UNC0638 and UNC0642 in expanded PTCL cell panels. Pharmacologic and genetic blockade of G9a significantly downregulated repressive histone mark H3K9me2, triggered simultaneous apoptotic and necroptotic cell death in PTCL cells, as confirmed by flow cytometry, transmission electron microscopy, western blot detection of cleaved caspase-3 and phosphorylated RIPK1/RIPK3/MLKL, and functional rescue assays with selective cell death pathway inhibitors Z-VAD-FMK and necrostatin-1. Integrated single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing analyses revealed prominent enrichment of oxidative stress signaling among genes persistently upregulated following CM272 treatment; direct DCFH-DA fluorescence measurement demonstrated massive intracellular reactive oxygen species (ROS) accumulation upon G9a inhibition, while ROS scavenger N-acetyl-L-cysteine fully reversed G9ai-induced proliferative suppression and cell death, confirming lethal oxidative stress as the core downstream effector of G9a targeting. Chromatin accessibility profiling and chromatin immunoprecipitation quantitative PCR validated that G9a mediates transcriptional silencing of activating transcription factor 3 (ATF3) via deposition of H3K9me2 at the ATF3 promoter locus, and G9a inhibition relieves this epigenetic repression to drive robust ATF3 reactivation. Functional knockdown of ATF3 abolished CM272-triggered ROS burst and partially rescued PTCL cell viability, and ROS depletion blunted ATF3 upregulation under G9a suppression, collectively establishing a self-amplifying ROS–ATF3 positive feedback loop that drives redox collapse and oxidative cell death in PTCL.

Immunohistochemical staining of PTCL tissue microarrays demonstrated markedly elevated G9a protein expression in lymphoma specimens relative to reactive lymphoid hyperplasia control tissues, and loss-of-function and overexpression cellular assays confirmed G9a acts as an oncogenic dependency to accelerate PTCL proliferation. Transcription factor ATF3 directly binds and activates the anti-proliferative tumor suppressor BTG1 promoter, and ATF3/BTG1 expression levels are significantly reduced in clinical PTCL samples and positively correlated with prolonged overall survival of PTCL patients, supporting the ATF3–BTG1 axis as a novel prognostic biomarker for this disease. Retrospective analysis of clinical chidamide-treated PTCL patient samples revealed low endogenous ATF3 expression confers intrinsic resistance to HDACi monotherapy, whereas combined dual epigenetic suppression of G9a and HDAC with CM272 plus chidamide produced synergistic anti-tumor activity across in vitro PTCL cell models, and significantly suppressed subcutaneous lymphoma growth, reduced Ki-67 proliferation index, and elevated tumoral ATF3 and BTG1 expression.

Collectively, our multi-omics, cellular and preclinical in vivo data identify histone methyltransferase G9a as a tractable epigenetic therapeutic vulnerability in PTCL, demonstrate CM272 exerts robust single-agent anti-lymphoma activity through activating the ATF3-dependent ROS cell death cascade, validate the ATF3–BTG1 axis as a prognostic biomarker and key modulator of HDACi drug sensitivity, and provide strong mechanistic preclinical rationale for dual G9a/HDAC epigenetic combinatorial therapy to overcome chidamide resistance and improve clinical outcomes for relapsed/refractory PTCL patients.

Hui Jin: No relevant conflicts of interest to declare.